Onshore manufacturing facility is expected to be based in Quebec and produce up to 100 million mRNA respiratory vaccine doses annually
Submission to regulators globally is based on phase 2/3 studies of mRNA-1273 in young children
Business EPS of €1.94, up 20.5% on a reported basis and 16.1% at CER, also benefitting from an improved effective tax rate
These bulk orders will contribute to the topline of the company as well as help in improving EBITDA of the company
This action makes Veklury the first approved Covid-19 treatment for children less than 12 years of age
Covaxin was earlier approved for children 12-18 years of age
Kaiser Permanente finds the Pfizer Covid-19 third dose vaccine protection against hospitalization from omicron wanes after 3 months
The proposed life sciences research and development centre in North of England region of UK will support acceleration of the company’s research in the areas of biotechnology, health and life sciences
Healthium Medtech, a company focused on products used in surgical, post-surgical and chronic care has ramped up its play in the global healthcare industry. In an interview with Thomas C. Thottathil, Editor, Indian Pharma Post, Anish Bafna, CEO and MD, Healthium Medtech outlines his plans
Immune response confirmed in stand-alone influenza vaccine and combination vaccine with a potential path forward for both
Subscribe To Our Newsletter & Stay Updated
